Analysts Project Modest Upside To Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 4, Scotiabank lifted its price target on the stock to $53 from $43, while maintaining a Sector Perform rating for its shares, citing Wall Street’s ‘modest expectations’ for the company’s pipeline.

Analysts Project Modest Upside in Bristol-Myers Squibb Company (BMY)

The firm said that results of several clinical trials were expected in 2026, which have not received much attention from investors yet. However, Scotiabank believes these have a significant risk or reward potential and could lead to a significant upside if the outcomes are favorable.

The adjustment follows Goldman Sachs’ update on Bristol-Myers Squibb Company (NYSE:BMY) earlier in the month on December 2, when it raised its price target for the stock to $57 from $51 and kept a Neutral rating on its shares.

Based on the recommendations and price targets from 27 analysts, the stock has a consensus Hold rating and a one-year average share price target of $53.41 as of December 5, representing an upside potential of 2.4%.

In other news, on December 3, Bristol-Myers Squibb Company (NYSE:BMY) said it would expand its ADEPT-2 study of the Alzheimer’s psychosis drug Cobenfy to additional patients after irregularities were observed at certain study sites. Trial results from the program are expected to be declared by the end of 2026.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company engaged in the discovery and development of innovative treatments for several serious diseases.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Drone Stocks to Buy Right Now and 8 Best Small-Cap Defense Stocks to Buy Right Now 

Disclosure: None.